Press Releases

The U.S. Food and Drug Administration (FDA) has approved INBRIJA™, a levodopa inhalation powder developed by Acorda Therapeutics, as a treatment for “off” periods in people with Parkinson’s disease (PD) who are treated with carbidopa/levodopa.

Quick Facts about INBRIJA™:

MIAMI & NEW YORK — NOVEMBER 7, 2018 —The Parkinson’s Foundation hosted the first national forum for women with Parkinson’s disease (PD) on October 19 at Baylor College of Medicine, a Parkinson’s Foundation Center of Excellence, in Houston, TX.

​MIAMI AND NEW YORK—October 30, 2018—The Parkinson’s Foundation will host a Caregiver Summit – “Cumbre Para Cuidadores” – geared specifically toward caregivers of people living with Parkinson’s disease (PD).

NEW YORK AND MIAMI—October 22, 2018—The Parkinson’s Foundation has achieved a 4-star rating from Charity Navigator, the nation's largest and most-utilized evaluator of charities.

The 4-star rating is the highest rating given only to nonprofit organizations that exceed industry standards and outperform peers, while demonstrating strong financial health and commitment to accountability and transparency.